Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
Director Matthew Fust has sold 12,195 shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on March 7, 2024, according to a recent SEC filing. The transaction was executed at an average price of $50.88 per share, resulting in a total value of $620,471.60.
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company committed to developing treatments for rare and ultra-rare diseases. The company focuses on serious, debilitating genetic diseases and has a diverse portfolio of products in various stages of clinical development.
Over the past year, Matthew Fust has sold a total of 12,195 shares of the company and has not made any purchases of the stock. This latest transaction continues a pattern of insider sales at Ultragenyx Pharmaceutical Inc, with a total of 19 insider sells and no insider buys over the past year.
Shares of Ultragenyx Pharmaceutical Inc were trading at $50.88 on the day of the sale, giving the company a market capitalization of $4.068 billion.
The stock's price-to-GF-Value ratio stands at 0.85, indicating that Ultragenyx Pharmaceutical Inc is modestly undervalued according to the GF Value. The GF Value is an intrinsic value estimate that takes into account historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling activity at Ultragenyx Pharmaceutical Inc.
The GF Value image above provides a visual representation of the stock's current valuation in relation to its GuruFocus Value.
For more detailed information on insider transactions at Ultragenyx Pharmaceutical Inc, interested individuals can refer to the SEC filing through the provided link.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
